Combined In Vitro/In Vivo Genome-Wide CRISPR Screens in Triple Negative Breast Cancer Identify Cancer Stemness Regulators in Paclitaxel Resistance

Scientists reported a combined in vitro/in vivo genome-wide CRISPR synthetic lethality screening approach in a relevant triple negative breast cancer cell line model to identify several targets responsible for the chemotherapy drug, paclitaxel resistance.